Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
Isolated limb perfusion (ILP) results in good response rates for locally advanced melanoma
(stage IIIB and IIIC, AJCC 2009). Outcome is influenced by stage of disease, reflecting the
aggressiveness of the melanoma. Our objective is to demonstrate at least a doubling of the
progression free survival for the patients having an adjuvant treatment by Ipilimumab in this
patient population with unfavourable characteristics. PFS ranges from 10-12 months. So at
least a doubling of this period would be a clinically highly significant result.